Sws Partners Abb Vie Inc. Transaction History

Sws Partners

$310 Million
Q3 2024

A detailed history of Sws Partners transactions in Abb Vie Inc. stock. As of the latest transaction made, Sws Partners holds 14,479 shares of ABBV stock, worth $2.62 Million. This represents 0.92% of its overall portfolio holdings.

Number of Shares

14,479

Previous 16,602 12.79%

Holding current value

$2.62 Million

Previous $2.85 Million 0.42%

% of portfolio

0.92%

Previous 0.86%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	SELL	$163.84 - $199.33 $347,832 - $423,177	-2,123 Reduced 12.79%	14,479 $2.86 Million
Q2 2024 Jul 17, 2024	BUY	$154.79 - $180.76 $55,105 - $64,350	356 Added 2.19%	16,602 $2.85 Million
Q1 2024 Apr 30, 2024	SELL	$159.82 - $182.1 $131,691 - $150,050	-824 Reduced 4.83%	16,246 $2.96 Million
Q4 2023 Feb 13, 2024	SELL	$137.6 - $154.97 $43,756 - $49,280	-318 Reduced 1.83%	17,070 $2.65 Million
Q3 2023 Nov 09, 2023	SELL	$133.59 - $154.65 $355,883 - $411,987	-2,664 Reduced 13.29%	17,388 $2.59 Million
Q2 2023 Aug 17, 2023	BUY	$132.51 - $164.9 $2.66 Million - $3.31 Million	20,052 New	20,052 $2.7 Million
Q2 2023 Jul 26, 2023	BUY	$132.51 - $164.9 $373,015 - $464,193	2,815 Added 16.33%	20,052 $2.7 Million
Q1 2023 May 09, 2023	SELL	$144.61 - $166.54 $93,707 - $107,917	-648 Reduced 3.62%	17,237 $2.75 Million
Q4 2022 Jan 30, 2023	BUY	$138.31 - $165.87 $187,963 - $225,417	1,359 Added 8.22%	17,885 $2.89 Million
Q3 2022 Nov 09, 2022	BUY	$134.21 - $153.93 $21,607 - $24,782	161 Added 0.98%	16,526 $2.22 Million
Q2 2022 Jul 28, 2022	SELL	$137.62 - $174.96 $279,093 - $354,818	-2,028 Reduced 11.03%	16,365 $2.51 Million
Q1 2022 May 05, 2022	SELL	$131.98 - $163.75 $265,015 - $328,810	-2,008 Reduced 9.84%	18,393 $2.99 Million
Q4 2021 Jan 25, 2022	SELL	$107.43 - $135.93 $105,066 - $132,939	-978 Reduced 4.57%	20,401 $2.76 Million
Q3 2021 Nov 08, 2021	SELL	$106.4 - $120.78 $1.32 Million - $1.5 Million	-12,430 Reduced 36.77%	21,379 $2.31 Million
Q2 2021 Aug 09, 2021	BUY	$105.21 - $117.21 $227,253 - $253,173	2,160 Added 6.82%	33,809 $3.81 Million
Q1 2021 May 17, 2021	BUY	$102.3 - $112.62 $392,013 - $431,559	3,832 Added 13.78%	31,649 $3.43 Million
Q4 2020 Mar 31, 2021	BUY	$80.49 - $108.67 $63,587 - $85,849	790 Added 2.92%	27,817 $2.98 Million
Q3 2020 Nov 13, 2020	BUY	$85.91 - $100.83 $853,258 - $1 Million	9,932 Added 58.1%	27,027 $2.37 Million
Q2 2020 Aug 13, 2020	SELL	$73.37 - $98.18 $207,050 - $277,063	-2,822 Reduced 14.17%	17,095 $1.62 Million
Q1 2020 May 14, 2020	SELL	$64.5 - $97.79 $476,268 - $722,081	-7,384 Reduced 27.05%	19,917 $1.52 Million
Q3 2019 Nov 15, 2019	BUY	$62.98 - $75.72 $1.72 Million - $2.07 Million	27,301 New	27,301 $1.81 Million
Q2 2019 Aug 13, 2019	SELL	$65.7 - $83.98 $1.31 Million - $1.67 Million	-19,934 Closed	0 $0
Q4 2018 Feb 04, 2019	SELL	$77.85 - $96.01 $558,885 - $689,255	-7,179 Reduced 26.48%	19,934 $1.84 Million
Q3 2018 Nov 14, 2018	BUY	$88.91 - $98.84 $496,829 - $552,317	5,588 Added 25.96%	27,113 $2.57 Million
Q2 2018 Aug 13, 2018	BUY	$89.78 - $106.23 $238,635 - $282,359	2,658 Added 14.09%	21,525 $1.99 Million
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $27,142 - $36,346	295 Added 1.59%	18,867 $1.73 Million
Q4 2017 Feb 15, 2018	BUY	$89.56 - $98.21 $1.66 Million - $1.82 Million	18,572	18,572 $1.8 Million

Others Institutions Holding ABBV

# of Institutions

3,849

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $320B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sws Partners, based on Form 13F filings with the SEC.

News

Stay updated on Sws Partners with notifications on news.

Account